Momentum: MACD histogram -0.124 and negatively expanding → selling pressure is still building.
RSI(6) 32.4: near oversold; can bounce, but not yet a confirmed reversal signal.
Levels: price 16.625 is sitting just above S1 16.488 (near-term support). Breakdown risk opens room toward S2 16.025.
Upside levels if it bounces: Pivot 17.237 first, then R1 17.985.
Pattern-based bias: modest positive skew (model indicates ~60% chance of small gains), but it conflicts with the current bearish trend structure.
Options Data
Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment: Put-heavy open interest (PCR 1.42) and even more put-heavy volume (1.77) → traders positioned defensively/hedging, not chasing upside.
Activity: Today’s volume 468; volume vs 30-day avg ~58% (not a panic/flush), while open interest is elevated (today vs OI avg ~92%).
Volatility: IV30 ~25.05 vs HV ~23.78 (IV slightly rich). IV percentile 75.6 suggests options are priced relatively expensively vs its own history → market is paying up for protection.
Technical Summary
Sell
9
Buy
2
Positive Catalysts
Q4 2025 results: reported >$70M in merger synergies and 3.9% same-store cash NOI growth (supports operational execution).
Q4 prints were ahead on key lines (FFO/revenue cited as exceeding expectations in headlines), which can underpin a short-term bounce off support.
If rates/REIT sentiment stabilize, high-quality healthcare REITs can re-rate quickly from depressed levels.
Neutral/Negative Catalysts
before a 2H26 ramp, creating near-term headwinds.
Financial Performance
Latest provided quarter: 2025/Q3
Revenue: $705.9M, +0.78% YoY (low growth).
Net income: -$117.3M, down -236.9% YoY; EPS -0.17 (REIT accounting can distort earnings, but it still reflects weak GAAP trend in the snapshot).
Gross margin: 58.65%, down 2.12% YoY (some margin pressure).
Recent quarter headlines (Q4 2025): operational synergies and NOI growth were positives, but forward FFO guidance was the market’s key concern.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes skew slightly negative/neutral: Wells Fargo cut PT to $18 from $19 (kept Equal Weight), citing near-term occupancy loss risk before 2H26 ramp.
Baird trimmed PT to $20 from $21 but kept Outperform.
Net Street view from this sample: mixed—one constructive (Outperform) but PT cuts and an Equal Weight stance suggest Wall Street sees limited near-term upside until occupancy/FFO trajectory improves.
Politicians/Congress: no recent congress trading data available (no signal from that channel).
Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 16.680
Low
16.71
Averages
19.23
High
21
Current: 16.680
Low
16.71
Averages
19.23
High
21
Argus
Marie Ferguson
Buy
to
Hold
downgrade
AI Analysis
2026-02-05
New
Reason
Argus
Marie Ferguson
Price Target
AI Analysis
2026-02-05
New
downgrade
Buy
to
Hold
Reason
Argus analyst Marie Ferguson downgraded Healthpeak Properties to Hold from Buy.
Wells Fargo
John Kilichowski
Equal Weight
downgrade
$19 -> $18
2026-02-03
Reason
Wells Fargo
John Kilichowski
Price Target
$19 -> $18
2026-02-03
downgrade
Equal Weight
Reason
Wells Fargo analyst John Kilichowski lowered the firm's price target on Healthpeak Properties to $18 from $19 and keeps an Equal Weight rating on the shares. The firm recently toured the South SF Life Science market, which is 16msf. The company's tone was positive but Wells estimates about 500bps of occ loss in Q4 and Q1 before the second half of 2026 expected ramp.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOC
